Literature DB >> 27469073

Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation.

Ankit K Rochani1, Sivakumar Balasubramanian1, Aswathy Ravindran Girija1, Sreejith Raveendran1, Ankita Borah1, Yutaka Nagaoka1, Yoshikata Nakajima1, Toru Maekawa1, D Sakthi Kumar2.   

Abstract

Heat Shock Protein 90 (Hsp90) has been extensively explored as a potential drug target for cancer therapies. 17- N-allylamino- 17-demethoxygeldanamycin (17AAG) was the first Hsp90 inhibitor to enter clinical trials for cancer therapy. However, native drug is being shown to have considerable anticancer efficacy against pancreatic cancer when used in combination therapy regime. Further, magnetic hyperthermia has shown to have promising effects against pancreatic cancer in combination with known cyto-toxic drugs under both target and non-targeted scenarios. Hence, in order to enhance the efficacy of 17AAG against pancreatic cancer, we developed poly (lactic-co-glycolic acid) (PLGA) coated, 17AAG and Fe3O4 loaded magnetic nanoparticle formulations by varying the relative concentration of polymer. We found that polymer concentration affects the magnetic strength and physicochemical properties of formulation. We were also able to see that our aqueous dispensable formulations were able to provide anti-pancreatic cancer activity for MIA PaCa-2 cell line in dose and time dependent manner in comparison to mice fibroblast cell lines (L929). Moreover, the in-vitro magnetic hyperthermia against MIA PaCa-2 provided proof principle that our 2-in-1 particles may work against cancer cell lines effectively.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  17AAG; Cancer chemotherapy; Hsp90 inhibitor; Nano formulation; Nanotechnology

Mesh:

Substances:

Year:  2016        PMID: 27469073     DOI: 10.1016/j.ijpharm.2016.07.048

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

Review 1.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

2.  HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.

Authors:  Arin N Graner; Justin E Hellwinkel; Alex M Lencioni; Helen J Madsen; Tessa A Harland; Paul Marchando; Ger J Nguyen; Mary Wang; Laura M Russell; Lynne T Bemis; Thomas J Anchordoquy; Michael W Graner
Journal:  Int J Hyperthermia       Date:  2016-12-20       Impact factor: 3.914

Review 3.  Nanotechnologies in Pancreatic Cancer Therapy.

Authors:  Ayesha Manzur; Adeolu Oluwasanmi; Darren Moss; Anthony Curtis; Clare Hoskins
Journal:  Pharmaceutics       Date:  2017-09-25       Impact factor: 6.321

Review 4.  Magnetic Hyperthermia for Cancer Treatment: Main Parameters Affecting the Outcome of In Vitro and In Vivo Studies.

Authors:  Vânia Vilas-Boas; Félix Carvalho; Begoña Espiña
Journal:  Molecules       Date:  2020-06-22       Impact factor: 4.411

Review 5.  Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Authors:  Tianqi Su; Bo Yang; Tianren Gao; Tongjun Liu; Jiannan Li
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

6.  Folic Acid-Decorated pH-Responsive Nanoniosomes With Enhanced Endocytosis for Breast Cancer Therapy: In Vitro Studies.

Authors:  Tahereh Rezaei; Mehdi Rezaei; Sara Karimifard; Farzaneh Mahmoudi Beram; Mohammad Sedigh Dakkali; Maryam Heydari; Soheil Afshari-Behbahanizadeh; Ebrahim Mostafavi; Dmitry Olegovich Bokov; Mohammad Javed Ansari; Bahareh Farasati Far; Iman Akbarzadeh; Chaiyavat Chaiyasut
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

7.  Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy.

Authors:  Srishti Agarwal; M Sheikh Mohamed; Sreejith Raveendran; Ankit K Rochani; Toru Maekawa; D Sakthi Kumar
Journal:  RSC Adv       Date:  2018-09-21       Impact factor: 4.036

8.  pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy.

Authors:  Farnaz Khodabakhsh; Mahsa Bourbour; Mohammad Tavakkoli Yaraki; Saina Bazzazan; Haleh Bakhshandeh; Reza Ahangari Cohan; Yen Nee Tan
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

9.  Folate-Targeted Curcumin-Loaded Niosomes for Site-Specific Delivery in Breast Cancer Treatment: In Silico and In Vitro Study.

Authors:  Banafsheh Honarvari; Sara Karimifard; Niyayesh Akhtari; Mehrnoush Mehrarya; Zahra Salehi Moghaddam; Mohammad Javed Ansari; Abduladheem Turki Jalil; Adrián Matencio; Francesco Trotta; Faten Eshrati Yeganeh; Bahareh Farasati Far; Mandana Kazem Arki; Mohammad Reza Naimi-Jamal; Hassan Noorbazargan; Zahra Asghari Lalami; Mohsen Chiani
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

Review 10.  Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.

Authors:  Sangiliyandi Gurunathan; Min-Hee Kang; Muhammad Qasim; Jin-Hoi Kim
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.